For a man who has never been shy about sharing his sanctimonious opinions, former President Barack Obama has been noticeably quiet about anti-Israel anarchists’ takeover of U.S. college campuses.

On Monday, Columbia University — Obama’s alma mater — announced it will not host its university-wide commencement ceremony for this year’s graduating class. That appears a response to the pro-Hamas demonstrations that have engulfed the school for weeks. The announcement came days after the university (finally) permitted law enforcement to arrest participants unlawfully occupying a school building.

One would imagine the erection of illegal encampments and harassment of Jewish students at Columbia and other American universities would prompt outcry from any former president. Donald Trump, for example, has repeatedly condemned these demonstrators and their anti-Israeli sentiments. But for Obama, the task is seemingly too difficult.

Since the launch of the Columbia encampments last month, Obama has issued a smattering of posts on X, none of which address leftists’ takeover of campuses throughout the country. While the former president wished Jews a happy Passover on April 22, he couldn’t be bothered to condemn the antisemitic behavior on display at his alma mater or any of America’s post-secondary institutions.

Obama’s Checkered Past

It goes without saying that if the aforementioned demonstrators were “MAGA Republicans” protesting an Islamic country and harassing Muslim students, legacy media “journalists” would be relentlessly spamming the phone lines and emails of every GOP official in the country asking for condemnation. They will never hold Democrats to the

The New York judge presiding over Manhattan District Attorney Alvin Bragg’s prosecution of former President Donald Trump has strictly limited the information a key witness for the Republican’s defense can testify about in court.

Bragg claims Trump violated the Federal Election Campaign Act (FECA) when his former attorney Michael Cohen paid pornographic film actress Stormy Daniels to keep quiet about an alleged affair. According to Bragg, because the cash changed hands ahead of the 2016 election, it should have been publicly reported as a campaign expenditure.

Judge Juan Merchan, a financial supporter of Trump’s campaign opponent with a “rabid pro-Democrat bias,” has gone along with this plan by entertaining Bragg’s weak case and gagging Trump. Merchan further hindered Trump’s legal efforts by declaring former FEC Chairman Bradley Smith is only allowed to testify about limited aspects of his job.

Smith professionally enforced campaign finance laws including the one Bragg has chosen to target Trump over. He has long asserted that “almost anything a candidate does can be interpreted as intended to “influence an election” but “not every expense that might benefit a candidate is an obligation that exists solely because the person is a candidate.”

In an April 15 article for The Federalist, Smith reiterated that almost all purchases by politicians could be construed as meeting the “for the purpose of influencing an election” clause in the FECA but are not scrutinized because they are classified as “personal use.” 

He noted that even if Trump met the threshold for “misreporting

Newly expanded genetic testing expands concerns about eugenics in assisted reproductive technology by allowing parents to choose which of their unborn children live and die based on their alleged predisposition to physical and mental conditions.

Orchid Health, whose motto is “Have healthy babies,” is the startup responsible for developing and marketing the first commercially available whole-genome-sequencing embryo test in nearly three dozen fertility facilities in the United States.

For $12,500, anyone who already paid the hefty price to undergo in vitro fertilization and create embryos can have five of them biopsied — the process of removing five cells out of the 120-cell embryo — by genetic screeners. The San Francisco-based company. Orchid claims its whole-genome analysis will help IVF customers “mitigate more risks” when choosing which of their unborn children to implant and carry to term.

The technology allegedly sequences more than 99 percent of an embryo’s DNA for potential diseases like Alzheimer’s, disorders like schizophrenia, cancers, defects, chromosomal abnormalities, forms of autism, and more.

Orchid achieves this by combining the results of preimplantation genetic testing for aneuploidy (PGT-A) with PGT for monogenic or single-gene diseases (PGT-M), and PGT for polygenic risk, or conditions that can manifest into adulthood. The screening then produces a report card with a long list of hypotheticals about an embryonic child’s “quality of life.”

Orchid claims to “adhere to the highest clinical and scientific standards.” But shortly after its December 2023 debut, the Psychiatric Genomics Consortium, an international coalition of more than 800 scientists,